Literature DB >> 11095615

Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.

J H Sohn1, H J Kaplan, H J Suk, P S Bora, N S Bora.   

Abstract

PURPOSE: To identify the molecules in normal human intraocular fluid (aqueous humor and vitreous) that inhibit the functional activity of the complement system.
METHODS: Aqueous humor and vitreous were obtained from patients with noninflammatory ocular disease at the time of surgery. Samples were incubated with normal human serum (NHS), and the mixture assayed for inhibition of the classical and alternative complement pathways using standard CH(50) and AH(50) hemolytic assays, respectively. Both aqueous humor and vitreous were fractionated by microconcentrators and size exclusion column chromatography. The inhibitory molecules were identified by immunoblotting as well as by studying the effect of depletion of membrane cofactor protein (MCP), decay-accelerating factor (DAF), and CD59 on inhibitory activity.
RESULTS: Both aqueous humor and vitreous inhibited the activity of the classical pathway (CH(50)). Microcentrifugation revealed the major inhibitory activity resided in the fraction with an M(r) >/= 3 kDa. Chromatography on an S-100-HR column demonstrated that the most potent inhibition was associated with the high-molecular-weight fractions (>/=19.5 kDa). In contrast to unfractionated aqueous and vitreous, fractions with an M(r) >/= 3 kDa also had an inhibitory effect on the alternative pathway activity (AH(50)). The complement regulatory activity in normal human intraocular fluid was partially blocked by monoclonal antibodies against MCP, DAF, and CD59. Immunoblot analysis confirmed the presence of these three molecules in normal intraocular fluid.
CONCLUSIONS: Our results demonstrate that normal human intraocular fluid (aqueous humor and vitreous) contains complement inhibitory factors. Furthermore, the high-molecular-weight factors appear to be the soluble forms of MCP, DAF, and CD59.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095615      PMCID: PMC1821086     

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  47 in total

Review 1.  Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster.

Authors:  M K Liszewski; T W Post; J P Atkinson
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

2.  Complement-inhibiting activity of human seminal plasma and semen quality.

Authors:  N A Chowdhury; M Kamada; M Takikawa; H Mori; H Gima; T Aono
Journal:  Arch Androl       Date:  1996 Mar-Apr

3.  Activated complement in inflamed aqueous humor.

Authors:  B J Mondino; M M Glovsky; L Ghekiere
Journal:  Invest Ophthalmol Vis Sci       Date:  1984-07       Impact factor: 4.799

4.  Hemolytic complement activity in aqueous humor.

Authors:  B J Mondino; H Rao
Journal:  Arch Ophthalmol       Date:  1983-03

5.  Complement levels in normal and inflamed aqueous humor.

Authors:  B J Mondino; H Rao
Journal:  Invest Ophthalmol Vis Sci       Date:  1983-03       Impact factor: 4.799

6.  Complement in tears from normal humans.

Authors:  G K Yamamoto; M R Allansmith
Journal:  Am J Ophthalmol       Date:  1979-10       Impact factor: 5.258

7.  Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

8.  Complement and complement regulatory proteins in human tears.

Authors:  M D Willcox; C A Morris; A Thakur; R A Sack; J Wickson; W Boey
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-01       Impact factor: 4.799

9.  Purification and functional properties of soluble forms of membrane cofactor protein (CD46) of complement: identification of forms increased in cancer patients' sera.

Authors:  T Seya; T Hara; K Iwata; S Kuriyama; T Hasegawa; Y Nagase; S Miyagawa; M Matsumoto; M Hatanaka; J P Atkinson
Journal:  Int Immunol       Date:  1995-05       Impact factor: 4.823

Review 10.  Membrane cofactor protein.

Authors:  M K Liszewski; J P Atkinson
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

View more
  22 in total

Review 1.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

2.  Recombinant membrane-targeted form of CD59 inhibits the growth of choroidal neovascular complex in mice.

Authors:  Nalini S Bora; Purushottam Jha; Valeriy V Lyzogubov; Sankaranarayanan Kaliappan; Juan Liu; Ruslana G Tytarenko; Deborah A Fraser; B Paul Morgan; Puran S Bora
Journal:  J Biol Chem       Date:  2010-08-24       Impact factor: 5.157

3.  Expression of functional recombinant von Willebrand factor-A domain from human complement C2: a potential binding site for C4 and CRIT.

Authors:  Kwok-Min Hui; George L Orriss; Tilman Schirmer; Bergljót Magnadóttir; Jürg A Schifferli; Jameel M Inal
Journal:  Biochem J       Date:  2005-08-01       Impact factor: 3.857

4.  Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration.

Authors:  Puran S Bora; Zhiwei Hu; Tongalp H Tezel; Jeong-Hyeon Sohn; Shin Goo Kang; Jose M C Cruz; Nalini S Bora; Alan Garen; Henry J Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-14       Impact factor: 11.205

Review 5.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

6.  Feasibility study of lamellar keratoplasty in a murine model.

Authors:  Ting Huang; Stephen R Planck; James T Rosenbaum; Ellen J Lee
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

7.  Complement regulatory protein CD46 protects against choroidal neovascularization in mice.

Authors:  Valeriy Lyzogubov; Xiaobo Wu; Purushottam Jha; Ruslana Tytarenko; Michael Triebwasser; Grant Kolar; Paula Bertram; Puran S Bora; John P Atkinson; Nalini S Bora
Journal:  Am J Pathol       Date:  2014-07-11       Impact factor: 4.307

8.  Role of NKT cells in anterior chamber-associated immune deviation.

Authors:  Jerry Y Niederkorn
Journal:  Expert Rev Clin Immunol       Date:  2009-03       Impact factor: 4.473

9.  Alternate serotype adenovector provides long-term therapeutic gene expression in the eye.

Authors:  Melissa M Hamilton; Gordon A Byrnes; Jason G Gall; Douglas E Brough; C Richter King; Lisa L Wei
Journal:  Mol Vis       Date:  2008-12-30       Impact factor: 2.367

10.  Mechanisms of immune privilege in the anterior segment of the eye: what we learn from corneal transplantation.

Authors:  Junko Hori
Journal:  J Ocul Biol Dis Infor       Date:  2008-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.